4 completed, 1 active not recruiting, 1 recruiting. 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 4, Active not recruiting 1, Recruiting 1 |
Follow Unresectable Gallbladder Carcinoma: new trials by email Literature Review of Unresectable Gallbladder Carcinoma trials Research Report on Unresectable Gallbladder Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 29 | 2026-11-01 | 2026-09-10 |
| Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) Binimetinib, Biopsy Procedure, Biospecimen Collection - Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 17 | 2024-02-09 | 2026-10-19 |
| Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Ramucirumab - Cholangiocarcinoma, Liver and Intrahepatic Bile Duct Carcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 61 | 2015-12-29 | 2023-06-15 |
| Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Stage III Intrahepatic Cholangiocarcinoma AJCC v7, Stage IIIA Gallbladder Cancer AJCC v7 | Phase 2 | Completed | M.D. Anderson Cancer Center | 62 | 2015-04-02 | 2022-02-02 |
| MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery Akt Inhibitor MK2206, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study - Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 8 | 2011-04-01 | 2016-06-17 |
| Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma Erlotinib Hydrochloride, Sorafenib Tosylate - Extrahepatic Bile Duct Adenocarcinoma, Gallbladder Adenocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 40 | 2010-04-01 | 2015-06-30 |
Gallbladder Neoplasms (6) · Cholangiocarcinoma (4) · Carcinoma, Hepatocellular (2) · Klatskin Tumor (2) · Bile Duct Neoplasms (1)
Adenocarcinoma (6) · Biliary Tract Diseases (6) · Biliary Tract Neoplasms (6) · Carcinoma (6) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Gallbladder Diseases (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms by Site (6) · Neoplasms, Glandular and Epithelial (6) · Liver Diseases (2) · Liver Neoplasms (2) · Bile Duct Diseases (1) · Cholangiocarcinoma (1)
1,2-diaminocyclohexaneplatinum II citrate (2) · Cisplatin (2) · Gemcitabine (2) · Magnetic Resonance Spectroscopy (2) · Platinum (2) · Specimen Handling (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Biopsy (1) · Disulfides (1) · Erlotinib Hydrochloride (1) · Fluorouracil (1) · Immunoglobulin G (1) · Leucovorin (1) · MK 2206 (1)
National Cancer Institute (NCI) (3) · M.D. Anderson Cancer Center (2) · Ohio State University Comprehensive Cancer Center (1)
United States (6)
Anthony El-Khoueiry (1) · Ardaman Shergill (1) · Milind Javle (1) · Rachna T Shroff (1) · Sameek Roychowdhury, MD, PhD (1) · Tanios Bekaii-Saab (1)
N01CM00070 (1), P30CA016058 (1), U10CA032102 (1), U10CA180821 (1)